Results from Phase II studies demonstrated that rilzabrutinib showed clinically meaningful outcomes in patients with warm ...
The FDA has granted orphan drug designation to rilzabrutinib for IgG4-related disease and warm autoimmune hemolytic anemia, ...
Sanofi's rilzabrutinib receives FDA orphan drug designation for two rare diseases. Clinical studies show meaningful response ...
The FDA bestows an orphan drug designation to Sanofi's rilzabrutinib for treating warm autoimmune hemolytic anemia and ...
Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to ...
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicinesDesignation granted for warm autoimmune ...
Raymond James Financial Inc. purchased a new position in Immunovant, Inc. (NASDAQ:IMVT – Free Report) in the fourth quarter, ...
Sanofi said that its Rilzabrutinib treatment was granted orphan drug designation, which is used in the U.S. by the Food and Drug Administration. The designation is a status assigned to a medicine ...
The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the ...
The silence in their home is heartbreaking. The Mignosa family has gone four months without their lab, Cooper—four months ...
Some health conditions, including autoimmune hemolytic anemia, can cause high mean corpuscular hemoglobin concentration (MCHC) results on a blood test. MCHC is a measure of the average ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results